Association between BRAF V600E mutation and regional lymph node metastasis in papillary thyroid carcinoma

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 1, 2015, Pages 793-799

  Lu, Junliang ^a   Gao, Jie ^a   Zhang, Jing ^a   Sun, Jian ^a   Wu, Huanwen ^a   Shi, Xiaohua ^a   Teng, Lianghong ^b   Liang, Zhiyong ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

BRAF; Intratumor heterogeneity; Lymph node metastasis

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA; DNA MUTATIONAL ANALYSIS; FEMALE; GENETICS; HUMAN; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; PATHOLOGY; POINT MUTATION; POLYMERASE CHAIN REACTION; THYROID TUMOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; POINT MUTATION; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS; YOUNG ADULT;

EID: 84923097201     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Witt RL, Ferris RL, Pribitkin EA, Sherman SI, Steward DL and Nikiforov YE. Diagnosis and management of differentiated thyroid cancer using molecular biology. The Laryngoscope 2013; 123: 1059-1064.
2. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE and Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003; 63: 1454-1457.
3. Zhang Z, Liu D, Murugan AK, Liu Z and Xing M. Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer. Endocr Relat Cancer 2014; 21: 161-173.
4. Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, Barbi F, Avenia N, Scipioni A, Verrienti A, Tosi E, Cavaliere A, Gulino A, Filetti S and Russo D. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab 2007; 92: 2840-2843.
5. Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, Fugazzola L, Czarniecka A, Jarzab B, O'Neill CJ, Sywak MS, Lam AK, Riesco-Eizaguirre G, Santisteban P, Nakayama H, Tufano RP, Pai SI, Zeiger MA, Westra WH, Clark DP, Clifton-Bligh R, Sidransky D, Ladenson PW, Sykorova V. ASsociation between braf v600e mutation and mortality in patients with papillary thyroid cancer. JAMA 2013; 309: 1493-1501.
6. Nikiforov YE. Molecular and Histopathologic Characteristics of Multifocal Papillary Thyroid Carcinoma. Am J Surg Pathol 2013; 37: 1586-91.
7. Lupi C, Giannini R, Ugolini C, Proietti A, Berti P, Minuto M, Materazzi G, Elisei R, Santoro M and Miccoli P. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. Journal of Clinical Endocrinology & Metabolism 2007; 92: 4085-4090.
8. Lim JY, Hong SW, Lee YS, Kim BW, Park CS, Chang HS and Cho JY. Clinicopathologic implications of the BRAFV600E mutation in papillary thyroid cancer; a subgroup analysis of 3130 cases in a single center. Thyroid 2013; 23: 1423-30.
9. Howell GM, Nikiforova MN, Carty SE, Hodak SP, Stang MT, McCoy KL, Nikiforov YE and Yip L. BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer. Annals of surgical oncology 2013; 20: 47-52.
10. Gouveia C, Can NT, Bostrom A, Grenert JP, van Zante A and Orloff LA. Lack of Association of BRAF Mutation With Negative Prognostic Indicators in Papillary Thyroid Carcinoma: The University of California, San Francisco, Experience. JAMA Otolaryngol Head Neck Surg 2013; 139: 1164-70.
11. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA and Swanton C. Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing. New Engl J Med 2012; 366: 883-892.
12. Vitale M. Intratumor BRAF V600E Heterogeneity and Kinase Inhibitors in the Treatment of Thyroid Cancer: A Call for Participation. Thyroid 2013; 23: 517-519.
13. Tufano RP, Teixeira GV, Bishop J, Carson KA and Xing M. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine (Baltimore) 2012; 91: 274-286.
14. Gandolfi G, Sancisi V, Torricelli F, Ragazzi M, Frasoldati A, Piana S and Ciarrocchi A. Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression. J Clin Endocrinol Metab 2013; 98: E934-942.
15. Liu S, Zhang B, Zhao Y, Chen P, Ji M, Hou P and Shi B. Association of BRAF (V600E) mutation with clinicopathological features of papillary thyroid carcinoma: a study on a Chinese population. Int J Clin Exp Pathol 2014; 7: 6922-6928.
16. Ito Y, Yoshida H, Kihara M, Kobayashi K, Miya A, Miyauchi A. BRAFV600E Mutation Analysis in Papillary Thyroid Carcinoma: Is it Useful for all Patients? World J Surg 2014; 38: 679-687.
17. Riesco-Eizaguirre G, Gutierrez-Martinez P, Garcia-Cabezas MA, Nistal M and Santisteban P. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I-targeting to the membrane. Endocr Relat Cancer 2006; 13: 257-269.
18. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M and Tuveson DA. Suppression of BRAF (V599E) in human melanoma abrogates transformation. Cancer Res 2003; 63: 5198-5202.
19. Cheung M, Sharma A, Madhunapantula SV and Robertson GP. Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res 2008; 68: 3429-3439.
20. Lito P, Pratilas Christine A, Joseph Eric W, Tadi M, Halilovic E, Zubrowski M, Huang A, Wong Wai L, Callahan Margaret K, Merghoub T, Wolchok Jedd D, de Stanchina E, Chandarlapaty S, Poulikakos Poulikos I, Fagin James A and Rosen N. Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas. Cancer Cell 2012; 22: 668-682.